Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo de TAR-200 em combinação com cetrelimabe ou TAR-200 isoladamente versus bacilo intravesical Calmette-Guérin (BCG) em participantes com câncer de bexiga não invasivo muscular de alto risco virgens de BCG (SunRISe-3)

24 de setembro de 2026 atualizado por: Janssen Research & Development, LLC

Um estudo randomizado de fase 3, aberto, multicêntrico, avaliando a eficácia e a segurança do TAR-200 em combinação com cetrelimabe ou TAR-200 isolado versus bacilo intravesical Calmette-Guérin (BCG) em participantes com alto risco virgens de BCG Câncer de Bexiga Não Músculo Invasivo

The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle invasive bladder cancer (HR-NMIBC), including high-grade papillary Ta, any T1, or carcinoma in situ (CIS), between TAR-200 plus cetrelimab (Group A) and TAR-200 alone (Group C) versus intravesical BCG (Group B).

Visão geral do estudo

Status

Ativo, não recrutando

Condições

Descrição detalhada

Bladder cancer is the tenth most common malignancy worldwide. About 75 percent (%) of bladder cancers are non-muscle invasive at diagnosis with approximately 25% of NMIBC patients have HR, NMIBC. The TAR-200/gemcitabine (JNJ-17000139) product is an intravesical drug delivery system regulated as an investigational drug. The drug constituent consists of gemcitabine and osmotic minitablets. Cetrelimab (JNJ-63723283) is a fully human immunoglobulin G4 (IgG4) kappa monoclonal antibody (mAb) that binds programmed-cell death protein (PD)-1. The mainstay of treatment for HR-NMIBC is transurethral resection of bladder tumor, followed by intravesical treatment with BCG. In this study metronomic dosing of intravesical gemcitabine, delivered via TAR-200, alone or in combination with cetrelimab will be evaluated and compared against intravesical BCG. The study consists of a Screening phase, Treatment phase, and Follow-up phase. The total duration of the study will be up to 5 years and 2 months. Efficacy, Safety, pharmacokinetics (PK), and biomarkers will be assessed at specific time points during the study.

Tipo de estudo

Intervencional

Inscrição (Real)

1135

Estágio

  • Fase 3

Acesso expandido

Aprovado para venda ao público. Consulte registro de acesso expandido.

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Cologne, Alemanha, 50968
        • Urologische Partnerschaft Koln UPK
      • Duisburg, Alemanha, 47169
        • Urologicum Duisburg
      • Erlangen, Alemanha, 91054
        • Universitatsklinikum Erlangen
      • Essen, Alemanha, 45147
        • Universitatsklinikum Essen
      • Frankfurt am Main, Alemanha, 60590
        • Universitaetsklinikum Frankfurt
      • Freiburg im Breisgau, Alemanha, 79106
        • Universitaetsklinikum Freiburg
      • Markkleeberg, Alemanha, 04416
        • Matthias Schulze - Germany
      • Mettmann, Alemanha, 40822
        • Urologie Neandertal Praxis Mettmann
      • München, Alemanha, 81675
        • Klinikum rechts der Isar an der Technischen Universitat Munchen
      • Münster, Alemanha, 48149
        • Universitatsklinikum Munster
      • Nuremberg, Alemanha, 90491
        • Medizinisches Versorgungszentrum - Urologie
      • Nuremberg, Alemanha, 90419
        • Klinikum Nurnberg Nord
      • Nürtingen, Alemanha, 72622
        • Studienpraxis Urologie Nurtingen
      • Regensburg, Alemanha, 93053
        • Caritas-Krankenhaus St. Josef
      • Tübingen, Alemanha, 72076
        • Universitat Tubingen
      • Buenos Aires, Argentina, C1199
        • Hospital Italiano de Buenos Aires
      • Buenos Aires, Argentina, C1417
        • Sociedade Beneficente de Senhoras Hospital Sirio Libanes
      • Córdoba, Argentina, X5016KEH
        • Hospital Privado Centro Medico de Cordoba
      • Córdoba, Argentina, 5000
        • Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
      • Córdoba, Argentina, X5000KPH
        • Centro Urologico Profesor Bengio
      • Mar del Plata, Argentina, B7602CBM
        • Hospital Privado de la Comunidad
      • Río Cuarto, Argentina, 5800
        • Instituto Medico Rio Cuarto
      • Heidelberg, Austrália, 3084
        • Austin Health
      • Macquarie University, Austrália, 2109
        • Macquarie University Hospital
      • Nedlands, Austrália, 6009
        • Hollywood Private Hospital
      • South Brisbane, Austrália, 4101
        • Mater Hospital Brisbane
      • Barretos, Brasil, 14784-400
        • Fundacao Pio XII
      • Bauru, Brasil, 17033-495
        • NAIC Nair Antunes Instituto do Cancer
      • Campinas, Brasil, 13083-888
        • Hospital das Clinicas da Universidade Estadual de Campinas UNICAMP
      • Curitiba, Brasil, 81520-060
        • Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer
      • Natal, Brasil, 59075-740
        • Liga Norte Riograndense Contra O Cancer
      • Porto Alegre, Brasil, 90050-170
        • Irmandade Santa Casa de Misericordia de Porto Alegre
      • Presidente Prudente, Brasil, 19013-050
        • Hospital Regional do Cancer Hospital de Esperanca
      • Salvador, Brasil, 41253-190
        • IDOR - Regional Bahia
      • Santa Cruz do Sul, Brasil, 96835-090
        • Hospital Ana Nery Santa Cruz do Sul
      • Santo André, Brasil, 09060-870
        • CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
      • São Paulo, Brasil, 01509 900
        • Fundacao Antonio Prudente A C Camargo Cancer Center
      • São Paulo, Brasil, 01246 000
        • Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo
      • São Paulo, Brasil, 05652 900
        • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
      • São Paulo, Brasil, 1321 001
        • Real e Benemerita Associacao Portuguesa de Beneficencia
      • Antwerp, Bélgica, 2020
        • ZNA Middelheim
      • Bruges, Bélgica, 8000
        • AZ Sint-Jan
      • Bruges, Bélgica, 8310
        • AZ Sint-Lucas
      • Ghent, Bélgica, 9000
        • AZ Maria Middelares
      • Ghent, Bélgica, 9000
        • UZ Gent
      • Libramont-Chevigny, Bélgica, 6800
        • Centre Hospitalier de l'Ardenne
      • Roeselare, Bélgica, 8800
        • AZ Delta
      • Sint-Niklaas, Bélgica, 9100
        • Vitaz
      • Wilrijk, Bélgica, 2610
        • GZA Ziekenhuizen- Campus St Augustinus
    • Nova Scotia
      • Halifax, Nova Scotia, Canadá, B3H 2Y9
        • Nova Scotia Health Authority
    • Ontario
      • Hamilton, Ontario, Canadá, L8N 4A6
        • St Josephs Healthcare Hamilton
      • Toronto, Ontario, Canadá, M5G 1Z5
        • Princess Margaret Cancer Centre University Health Network
    • Quebec
      • Montreal, Quebec, Canadá, H2X 3E4
        • CHUM - Centre hospitalier universitaire de Montreal
      • Québec, Quebec, Canadá, G1J1Z4
        • CHU de Quebec Universite Laval Hopital de l Enfant Jesus
      • Saint Jerome Quebec, Quebec, Canadá, J7Z 2V4
        • Unite de Recherche Clinique du CISSS des Laurentides
      • Beijing, China, 100730
        • Beijing Hospital
      • Beijing, China, 100034
        • Peking University First Hospital
      • Beijing, China, 101100
        • Beijing Luhe Hospital, Capital Medical University
      • Changchun, China, 130499
        • The First Bethune Hospital of Jilin University
      • Changsha, China, 410013
        • Hunan Province Cancer Hospital
      • Chengdu, China, 610044
        • West China Hospital Sichuan University
      • Chongqing, China, 400000
        • Chongqing University Cancer Hospital
      • Deyang, China, 618000
        • People's Hospital of Deyang City
      • Guangzhou, China, 430030
        • Sun Yat Sen University Cancer Center
      • Hangzhou, China, 310000
        • Zhejiang Provincial People's Hospital
      • Hangzhou, China, 310016
        • Sir Run Run Shaw Hospital Zhejiang University School of Medicine
      • Nanjing, China, 210008
        • Nanjing Drum Tower Hospital
      • Ningbo, China, 315010
        • The First Affiliated Hospital of Ningbo University
      • Shanghai, China, 200025
        • Ruijing Hospital Affiliated To Shanghai Jiaotong University School Of Medicine
      • Shanghai, China, 200400
        • Huadong Hospital Affiliated to Fudan University
      • Shenyang, China, 110004
        • Shengjing Hospital Of China Medical University
      • Tianjin, China, 300211
        • The Second Hospital Of Tianjin Medical University
      • Wenzhou, China, 325000
        • The First Affiliated Hospital of Wenzhou Medical University
      • Wuhan, China, 430030
        • TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology
      • Xi'an, China, 710061
        • First Affiliated Hospital of Medical College of Xi'an Jiaotong University
      • Yantai, China, 264000
        • Yantai Yuhuangding Hospital
      • Zhengzhou, China, 450008
        • Henan Cancer Hospital
      • Busan, Coréia do Sul, 49241
        • Pusan National University Hospital
      • Cheongju-si, Coréia do Sul, 28644
        • Chungbuk National University Hospital
      • Daegu, Coréia do Sul, 41404
        • Kyungpook National University Chilgok Hospital
      • Daegu, Coréia do Sul, 42601
        • Keimyung University Dongsan Hospital
      • Gyeonggi-do, Coréia do Sul, 10408
        • National Cancer Center
      • Jeollanam-do, Coréia do Sul, 58128
        • Chonnam National University Hwasun Hospital
      • Seoul, Coréia do Sul, 03080
        • Seoul National University Hospital
      • Seoul, Coréia do Sul, 03722
        • Severance Hospital Yonsei University Health System
      • Seoul, Coréia do Sul, 06351
        • Samsung Medical Center
      • Seoul, Coréia do Sul, 03181
        • Kangbuk Samsung Hospital
      • Seoul, Coréia do Sul, 06591
        • The Catholic University of Korea Seoul St Marys Hospital
      • Seoul, Coréia do Sul, 02841
        • Korea University Anam Hospital
      • A Coruña, Espanha, 15006
        • Hosp Univ A Coruna
      • Algeciras, Espanha, 11207
        • Hosp. Punta de Europa
      • Barcelona, Espanha, 08025
        • Fund. Puigvert
      • Cadiz, Espanha, 11009
        • Hosp. Puerta Del Mar
      • Castellon, Espanha, 12004
        • Hosp. Gral. Univ. de Castellon
      • L'Hospitalet de Llobregat, Espanha, 08907
        • Hosp. Univ. de Bellvitge
      • Lugo, Espanha, 27003
        • Hosp. Univ. Lucus Augusti
      • Madrid, Espanha, 28041
        • Hosp. Univ. 12 de Octubre
      • Madrid, Espanha, 28046
        • Hosp. Univ. La Paz
      • Madrid, Espanha, 28027
        • Clinica Univ. de Navarra
      • Málaga, Espanha, 29010
        • Hosp Virgen de La Victoria
      • Santander, Espanha, 39008
        • Hosp. Univ. Marques de Valdecilla
      • Valencia, Espanha, 46010
        • Hosp. Clinico Univ. de Valencia
    • Arizona
      • Scottsdale, Arizona, Estados Unidos, 85259
        • Mayo Clinic
    • Arkansas
      • Little Rock, Arkansas, Estados Unidos, 72211
        • Arkansas Urology
    • California
      • Long Beach, California, Estados Unidos, 90822
        • VA Long Beach Health Care System
      • Los Alamitos, California, Estados Unidos, 90720
        • Genesis Research, LLC - West Coast Urology
      • Los Angeles, California, Estados Unidos, 90048
        • Cedars Sinai Medical Center
      • Sacramento, California, Estados Unidos, 95630
        • UC Davis Comprehensive Cancer Center
      • San Diego, California, Estados Unidos, 92123
        • Genesis Research
      • Santa Monica, California, Estados Unidos, 90404
        • Providence Saint Johns Cancer Institute
      • Santa Rosa, California, Estados Unidos, 95403
        • Providence Medical Foundation
    • Colorado
      • Lakewood, Colorado, Estados Unidos, 80228
        • Colorado Clinical Research
    • Florida
      • Hialeah, Florida, Estados Unidos, 33016
        • Urological Research Network
      • Orlando, Florida, Estados Unidos, 32806
        • Orlando Health Cancer Institute
      • Sarasota, Florida, Estados Unidos, 34239
        • Sarasota Memorial Hospital
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30303
        • Grady Memorial Hospital
      • Atlanta, Georgia, Estados Unidos, 30322
        • The Emory Clinic Department of Urology
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60611
        • Northwestern University
      • Lisle, Illinois, Estados Unidos, 60532
        • Duly Health and Care
      • Quincy, Illinois, Estados Unidos, 62301
        • Blessing Hospital
    • Indiana
      • Carmel, Indiana, Estados Unidos, 46032
        • Urology of Indiana
      • Jeffersonville, Indiana, Estados Unidos, 47130
        • First Urology
    • Kansas
      • Merriam, Kansas, Estados Unidos, 66204
        • AMR Kansas City Oncology
      • Wichita, Kansas, Estados Unidos, 67226
        • Wichita Urology Group
    • Maryland
      • Hanover, Maryland, Estados Unidos, 21076
        • Chesapeake Urology Research Associates
    • Massachusetts
      • Burlington, Massachusetts, Estados Unidos, 01805
        • Lahey Hospital & Medical Center
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • University of Michigan
    • Minnesota
      • Minneapolis, Minnesota, Estados Unidos, 55455
        • University Of Minnesota
      • Rochester, Minnesota, Estados Unidos, 55905
        • Mayo Clinic Rochester
    • Nebraska
      • Omaha, Nebraska, Estados Unidos, 68114
        • The Urology Center, PC
    • New Jersey
      • Camden, New Jersey, Estados Unidos, 08103
        • Cooper Health System MD Anderson Cancer Center at Cooper
    • New York
      • New York, New York, Estados Unidos, 10029
        • Icahn School of Medicine at Mt. Sinai
      • New York, New York, Estados Unidos, 10010
        • VA NY Harbor Healthcare System
      • Syracuse, New York, Estados Unidos, 13210
        • SUNY Upstate Med Univ
      • Syracuse, New York, Estados Unidos, 13210
        • Associated Medical Professionals of Ny
    • North Carolina
      • Greenville, North Carolina, Estados Unidos, 27834
        • Vidant Urology - Greenville
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44195
        • Cleveland Clinic
      • Gahanna, Ohio, Estados Unidos, 43230
        • Central Ohio Urology Group
    • Pennsylvania
      • Bala-Cynwyd, Pennsylvania, Estados Unidos, 19004
        • Centers for Advanced Urology LLC d b a MidLantic Urology
      • Philadelphia, Pennsylvania, Estados Unidos, 19107
        • Thomas Jefferson University Hospital
      • Pittsburgh, Pennsylvania, Estados Unidos, 15232
        • UPMC Shadyside Hospital
    • South Carolina
      • Myrtle Beach, South Carolina, Estados Unidos, 29572
        • Carolina Urologic Research Center
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37232
        • Vanderbilt University Medical Center
      • Nashville, Tennessee, Estados Unidos, 37209
        • Urology Associates
    • Texas
      • Austin, Texas, Estados Unidos, 78745
        • Urology Austin
      • Dallas, Texas, Estados Unidos, 75231
        • Urology Clinics of North Texas
      • Houston, Texas, Estados Unidos, 77030
        • Houston Methodist Hospital
      • Houston, Texas, Estados Unidos, 77027
        • Houston Metro Urology
      • San Antonio, Texas, Estados Unidos, 78229
        • Urology San Antonio Research
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84112
        • Huntsman Cancer Institute
      • Salt Lake City, Utah, Estados Unidos, 84148
        • George E. Wahlen VAMC
    • Virginia
      • Virginia Beach, Virginia, Estados Unidos, 23462
        • Urology Of Virginia, Pllc
    • Washington
      • Spokane, Washington, Estados Unidos, 99202
        • Spokane Urology
      • Bordeaux, França, 33000
        • Polyclinique Bordeaux Nord Acquitaine
      • Clermont-Ferrand, França, 63003
        • CHU Gabriel-Montpied
      • Grenoble, França, 38043
        • CHU Grenoble
      • Limoges, França, 87000
        • Polyclinique de Limoges - Francois Chenieux
      • Lyon, França, 69437
        • Hôpital Edouard Herriot
      • Nantes, França, 44093
        • CHU de Nantes hotel Dieu
      • Nîmes, França, 30029
        • CHU Nimes
      • Orléans, França, 45067
        • Centre Hospitalier Regional d'Orleans (CHRO) - Hopital La Source
      • Paris, França, 75013
        • Hôpital Universitaire Pitié-Salpêtrière
      • Paris, França, 75018
        • APHP - Hopital Bichat - Claude Bernard
      • Paris, França, 75960
        • Groupe Hospitalier Diaconesses Croix Saint Simon
      • Paris, França, 75015
        • Hopital Europeen Georges-Pompidou
      • Quint-Fonsegrives, França, 31130
        • Clinical La Croix Du Sud - Ramsay Santé
      • Rennes, França, 35000
        • Chu Rennes Hopital Pontchaillou
      • Strasbourg, França, 67200
        • Institut de Cancerologie Strasbourg Europe ICANS
      • Toulouse, França, 31059
        • CHU Rangueil
      • Hoofddorp, Holanda, 2134 TM
        • Spaarne Gasthuis
      • Nijmegen, Holanda, 6524 KD
        • Canisius-Wilhelmina Ziekenhuis
      • Nijmegen, Holanda, 6525 GA
        • Radboud Umcn
      • Acquaviva delle Fonti, Itália, 70021
        • Generale Regionale F. Miulli
      • Asti, Itália, 14100
        • Ospedale Cardinal Massaia
      • Avellino, Itália, 83100
        • Ospedale San Giuseppe Moscati di Avellino
      • Castelfranco Veneto, Itália, 31033
        • Ospedale San Giacomo Apostolo, Guardia pediatrica territoriale
      • Milan, Itália, 20141
        • Istituto Europeo di Oncologia
      • Milan, Itália, 20132
        • Ospedale San Raffaele di Milano
      • Naples, Itália, 80138
        • Fondazione G Pascale Istituto Nazionale Tumori IRCCS
      • Ravenna, Itália, 48121
        • Ospedale S. Maria Delle Croci
      • Rome, Itália, 00128
        • Istituto Nazionale Tumori Regina Elena
      • Fuji-shi, Japão, 417-8567
        • Fuji City General Hospital
      • Kanazawa, Japão, 920 8641
        • Kanazawa University Hospital
      • Kashihara-shi, Japão, 634-8522
        • Nara Medical University Hospital
      • Kisarazu-shi, Japão, 292-8535
        • Kimitsu Chuo Hospital
      • Kobe, Japão, 650 0047
        • Kobe City Medical Center General Hospital
      • Kumamoto, Japão, 860-0008
        • National Hospital Organization Kumamoto Medical Center
      • Nagano, Japão, 381-8551
        • Nagano Municipal Hospital
      • Nagasaki, Japão, 852-8501
        • Nagasaki University Hospital
      • Nagasaki, Japão, 852-8511
        • JRC Nagasaki Genbaku Hospital
      • Narashino-shi, Japão, 275-8580
        • Saiseikai Narashino Hospital
      • Toon-shi, Japão, 791-0295
        • Ehime University Hospital
      • Toyama, Japão, 930 0194
        • Toyama University Hospital
      • Ube, Japão, 755-8505
        • Yamaguchi University Hospital
      • Yokohama, Japão, 232 0024
        • Yokohama City University Medical Center
      • Mexico City, México, 14308
        • Consultorio Medico dentro del Hospital Angeles Acoxpa
      • Monterrey, México, 64460
        • Hospital Universitario Dr Jose Eleuterio Gonzalez
      • Monterrey, México, 64710
        • Avix Investigacion Clinica S C
      • Mérida, México, 97000
        • Eme Red Hospitalaria
      • San Luis Potosí City, México, 78260
        • Oncologico Potosino
      • Bialystok, Polônia, 15 276
        • Uniwersytecki Szpital Kliniczny w Bialymstoku
      • Bydgoszcz, Polônia, 85 048
        • IN VIVO Sp. z o.o
      • Lublin, Polônia, 20 708
        • Wojewodzki Szpital Specjalistyczny im Stefana Kardynala Wyszynskiego SPZOZ
      • Piotrkow Trybunalski, Polônia, 97 300
        • Centrum Medyczne
      • Poznan, Polônia, 61 731
        • Clinical Research Center sp z o o MEDIC R s k
      • Słupsk, Polônia, 76-200
        • Wojewodzki Szpital Specjalistyczny im Janusza Korczaka
      • Warsaw, Polônia, 02-781
        • Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
      • Warsaw, Polônia, 02-647
        • Provita Poliklinika
      • Wroclaw, Polônia, 50 556
        • Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu
      • Coimbra, Portugal, 3000-075
        • Ipo Coimbra
      • Lisbon, Portugal, 1769 001
        • Uls Santa Maria - Hosp. Santa Maria
      • Vila Nova de Gaia, Portugal, 4434 502
        • Uls Gaia Espinho
      • Edinburgh, Reino Unido, EH4 2XU
        • Western General Hospital
      • London, Reino Unido, W6 8RF
        • Charing Cross Hospital
      • London, Reino Unido, SW3 6JJ
        • The Royal Marsden NHS Trust
      • London, Reino Unido, EC1A 7BE
        • St Bartholomews Hospital
      • Plymouth, Reino Unido, PL6 8DH
        • Derriford Hospital
      • Scunthorpe, Reino Unido, DN15 7BH
        • Scunthorpe General Hospital
      • Sheffield, Reino Unido, S10 2JF
        • Sheffield Teaching Hospitals NHS Foundation Trust
      • Stevenage, Reino Unido, SG1 4AB
        • Lister Hospital
      • Truro, Reino Unido, TR1 3LJ
        • Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital
      • Kaohsiung City, Taiwan, 833
        • Chang Kung Memorial Hospital
      • Kaohsiung City, Taiwan, 807
        • Kaohsiung Medical University Chung Ho Memorial Hospital
      • Taichung, Taiwan, 404
        • China Medical University Hospital
      • Taichung, Taiwan, 40705
        • Taichung Veterans General Hospital
      • Taipei, Taiwan, 11217
        • Taipei Veterans General Hospital
      • Taoyuan, Taiwan, 33382
        • Linkou Chang Gung Memorial Hospital
      • Brno, Tcheca, 65691
        • Fakultni nemocnice u sv. Anny v Brne
      • Hradec Králové, Tcheca, 500 05
        • Fakultni nemocnice Hradec Kralove
      • Liberec, Tcheca, 460 01
        • Krajská nemocnice Liberec a.s.
      • Olomouc, Tcheca, 779 00
        • Fakultni nemocnice Olomouc
      • Prague, Tcheca, 100 34
        • Fakultni nemocnice Kralovske Vinohrady
      • Prague, Tcheca, 15006
        • Fakultni nemocnice v Motole
      • Prague, Tcheca, 140 59
        • Thomayerova nemocnice, Onkologicka klinika
      • Bangalore, Índia, 560027
        • Health Care Global Enterprises pvt Ltd
      • Chandigarh, Índia, 160012
        • Post Graduate Institute of Medical Education And Research PGIMER
      • Gurugram, Índia, 122001
        • Artemis Hospital
      • Kolkata, Índia, 700094
        • Netaji Subhas chandra Bose Cancer Research Institute
      • Mumbai, Índia, 400012
        • Tata Memorial Hospital
      • Pune, Índia, 411040
        • CIMET s Inamdar Multispeciality Hospital

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Histologically confirmed initial diagnosis by local pathology (within 90 days of the most recent signed informed consent) of high grade non-muscle invasive bladder cancer (HR-NMIBC) (high-grade Ta, any T1 or carcinoma in-situ [CIS]), in participants who are Bacillus Calmette Guérin (BCG)-naïve
  • BCG-naïve (participants who have not received prior intravesical BCG or who previously received but stopped BCG more than 3 years before date of randomization are eligible)
  • All visible papillary disease must be fully resected (absent) prior to date of randomization and documented at baseline cystoscopy. Local urine cytology at screening must be negative or atypical (for high-grade urothelial carcinoma [HGUC]) for patients with papillary only disease (without CIS)
  • Eastern Cooperative Oncology Group (ECOG) performance status Grade 0, 1, or 2
  • All adverse events associated with any prior surgery and/or intravesical therapy must have resolved to common terminology criteria for adverse events (CTCAE) version 5.0 Grade less than (<) 2 prior to date of randomization
  • Participants must be willing to undergo all study procedures

Exclusion Criteria:

  • Presence or history of histologically confirmed, muscle invasive, locally advanced, nonresectable, or metastatic urothelial carcinoma (that is, greater than and equal to [>=] T2)
  • Must not have had urothelial carcinoma or histological variant at any site outside of the urinary bladder (that is, urethra, ureter, or renal pelvis). Ta/any T1/CIS of the upper urinary tract (including renal pelvis and ureter) is allowable if treated with complete nephroureterectomy more than 24 months prior to randomization
  • Presence of any bladder or urethral anatomic feature (example, urethral stricture) that, in the opinion of the investigator, may prevent the safe insertion, indwelling use, removal of TAR-200 or administration of intravesical BCG. Participants with tumors involving the prostatic urethra in men will be excluded
  • A history of clinically significant polyuria with recorded 24-hour urine volumes greater than 4000 milliliters (mL)
  • Indwelling catheters are not permitted; however, intermittent catheterization is acceptable

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Treatment Group A: TAR-200 + Cetrelimab

Participants will receive intravesical TAR-200 once every 3 weeks (Q3W) and cetrelimab.

Cetrelimab will be administered.

Outros nomes:
  • JNJ-63723283

TAR-200 will be administered intravesically.

Outros nomes:
  • JNJ-17000139
Comparador Ativo: Treatment Group B: Bacillus Calmette-Guerin (BCG) Vesiculture

Participants will receive intravesical BCG once every week for 6 weeks (induction) and then followed by once every week for 3 weeks starting at Weeks 12, 24, 48, 72, and 96 (maintenance).

BCG will be administered intravesically.

Experimental: Treatment Group C: TAR-200 Alone

Participants will receive intravesical TAR-200 alone once Q3W.

TAR-200 will be administered intravesically.

Outros nomes:
  • JNJ-17000139

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Event-free Survival (EFS)
Prazo: Up to 5 years 2 months

EFS is defined as the time from randomization to either the time of the first recurrence of high-risk disease, progression, or death due to any cause, whichever occurs first. For participants with carcinoma In-situ (CIS), persistent disease at 6 months (Week 24) is also considered an EFS event. Progression is defined as: an increase of stage from Ta to T1 or from CIS to T1 or progression to muscle invasive bladder cancer (MIBC) (T greater than or equal to [>=] 2) or to lymph node (N+) or to distant disease (M+), whichever occurs first.

Up to 5 years 2 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Overall Complete Response (CR) Rate
Prazo: Up to 5 years 2 months

Overall CR will be measured by determining the percentage of participants with CIS who have no presence of high-risk disease at 6 months.

Up to 5 years 2 months
Duration of CR
Prazo: Up to 5 years 2 months

Duration of CR is defined from the time of first CR achieved to first evidence of recurrence, progression or death due to any cause (whichever occurs first) for participants who achieve a CR.

Up to 5 years 2 months
Recurrence-Free Survival (RFS)
Prazo: Up to 5 years 2 months

RFS is defined as the time from randomization to the time of the first recurrence of high-risk disease, or death due to any cause, whichever occurs first.

Up to 5 years 2 months
Time to Progression (TTP)
Prazo: Up to 5 years 2 months

TTP is defined as the time from randomization to the date of first documented evidence of disease progression or death due to disease progression, whichever occurs first.

Up to 5 years 2 months
Overall Survival (OS)
Prazo: Up to 5 years 2 months

OS is defined as the time from randomization to death, due to any cause.

Up to 5 years 2 months
Cancer Specific Survival (CSS)
Prazo: Up to 5 years 2 months

CSS is defined as the time from randomization to the date of death due to bladder cancer.

Up to 5 years 2 months
Number of Participants with Adverse Events (AEs) by Grades According to Common Terminology Criteria for Adverse Events (CTCAE)
Prazo: Up to 5 years 2 months

Number of participants with AEs by severity grade as assessed by CTCAE version 5 will be reported. Grade refers to the severity of AE as follows: Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life-threatening; Grade 5- Death related to adverse event.

Up to 5 years 2 months
Number of Participants with Adverse Events (AEs)
Prazo: Up to 5 years 2 months

Number of participants with AEs will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.

Up to 5 years 2 months
Number of Participants with Change from Baseline in Laboratory Abnormalities
Prazo: Up to 5 years 2 months

Number of participants with change from baseline in laboratory abnormalities will be reported. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1- Mild, Grade 2- Moderate, Grade 3- Severe, Grade 4- Life-threatening, and Grade 5- Death related to adverse event.

Up to 5 years 2 months
Number of Participants with Change from Baseline in Vital Signs Abnormalities
Prazo: Up to 5 years 2 months

Number of participants with change from baseline in vital signs (blood pressure [systolic and diastolic], heart rate, temperature, and weight) abnormalities will be reported.

Up to 5 years 2 months
Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of life Questionnaire - Non-muscle Invasive Bladder Cancer EORTC QLQ- NMIBC 24
Prazo: Up to 5 years 2 months

EORTC QLQ-NMIBC 24 is a 24-item questionnaire for evaluating the Health-related quality of life (HRQoL) of participants with superficial (non-muscle-invasive) bladder cancer. The questionnaire is designed to supplement the quality of life questionnaire (QLQ-C30) and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much).

Up to 5 years 2 months
Time to Symptom Deterioration as Assessed by EORTC-QLQ-NMIBC 24 Scores
Prazo: Up to 5 years 2 months

EORTC QLQ-NMIBC 24 is a 24-item questionnaire for evaluating the HRQoL of participants with superficial (non-muscle-invasive) bladder cancer. The questionnaire is designed to supplement the QLQ-C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much).

Up to 5 years 2 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Diretor de estudo: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

23 de março de 2023

Conclusão Primária (Estimado)

18 de setembro de 2029

Conclusão do estudo (Estimado)

18 de setembro de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

27 de janeiro de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

27 de janeiro de 2023

Primeira postagem (Real)

6 de fevereiro de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

25 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

24 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • CR109223
  • 2020-004506-64 (Número EudraCT)
  • 17000139BLC3002 (Outro identificador: Janssen Research & Development, LLC)
  • 2023-507187-39-00 (Identificador de registro: EUCT number)
  • 2023 (Concessão/Contrato do NIH dos EUA)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever